MAREA THERAPEUTICS, A SUBSIDIARY OF LISATA THERAPEUTICS, ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF MAR002, A POTENTIAL BEST-IN-DISEASE INVESTIGATIONAL THERAPY FOR THE TREATMENT OF ACROMEGALY

Reuters · 1d ago

Please log in to view news